Aldehyde dehydrogenase 2-mediated aldehyde metabolism promotes tumor immune evasion by regulating the NOD/VISTA axis
Journal for ImmunoTherapy of Cancer · 2023-12 · 11 (12) · e007487
DOI: 10.1136/jitc-2023-007487 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 07.12.2023. Verfasst von Yuru Chen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Chongqing Key Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Neoplasms. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Chongqing Graduate Tutor Team Construction Project/Chongqing Education Commission Foundation, Chongqing medical scientific research project/Joint project of Chongqing Health Commission and Science and Technology Bureau, CQMU Program for Youth Innovation in Future Medicine.
Abstract (Originalsprache)
Background
Aldehyde dehydrogenase 2 (ALDH2) is a crucial enzyme involved in endogenous aldehyde detoxification and has been implicated in tumor progression. However, its role in tumor immune evasion remains unclear.
Methods
Here, we analyzed the relationship between ALDH2 expression and antitumor immune features in multiple cancers. ALDH2 knockout tumor cells were then established using CRISPR/Cas9 system. In immunocompetent breast cancer EMT6 and melanoma B16-F10 mouse models, we investigated the impact of ALDH2 blockade on cytotoxic T lymphocyte function and tumor immune microenvironment by flow cytometry, mass cytometry, Luminex liquid suspension chip detection, and immunohistochemistry. Furthermore, RNA sequencing, flow cytometry, western blot, chromatin immunoprecipitation assay, and luciferase reporter assays were employed to explore the detailed mechanism of ALDH2 involved in tumor immune evasion. Lastly, the synergistic therapeutic efficacy of blocking ALDH2 by genetic depletion or its inhibitor disulfiram in combination with immune checkpoint blockade (ICB) was investigated in mouse models.
Results
In our study, we uncovered a positive correlation between the expression level of ALDH2 and T-cell dysfunction in multiple cancers. Furthermore, blocking ALDH2 significantly suppressed tumor growth by enhancing cytotoxic activity of CD8 + T cells and reshaping the immune landscape and cytokine milieu of tumors in vivo . Mechanistically, inhibiting ALDH2-mediated metabolism of aldehyde downregulated the expression of V-domain Ig suppressor of T-cell activation (VISTA) via inactivating the nucleotide oligomerization domain (NOD)/nuclear factor kappa-B (NF-κB) signaling pathway. As a result, the cytotoxic function of CD8 + T cells was revitalized. Importantly, ALDH2 blockade markedly reinforced the efficacy of ICB treatment.
Conclusions
Our data delineate that ALDH2-mediated aldehyde metabolism drives tumor immune evasion by activating the NOD/NF-κB/VISTA axis. Targeting ALDH2 provides an effective combinatorial therapeutic strategy for immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Chongqing Key Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
- Department of Endocrine and Breast Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
- Department of Breast Disease, Chongqing University Cancer Hospital, Chongqing, China.
- Department of Oncology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
- Department of Respiratory, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
- Department of Oncology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
ORCID-Profile: Hongzhong Li
Förderung
- Chongqing Graduate Tutor Team Construction Project/Chongqing Education Commission Foundation
- Chongqing medical scientific research project/Joint project of Chongqing Health Commission and Science and Technology Bureau
- CQMU Program for Youth Innovation in Future Medicine
- Natural Science Foundation of Chongqing Municipality
- National Natural Science Foundation of China
Zitieren
APA
Chen, Y., Sun, J., Liu, J., Wei, Y., Wang, X., Fang, H., Du, H., Huang, J., Li, Q., Ren, G., Wang, X., & Li, H. (2023). Aldehyde dehydrogenase 2-mediated aldehyde metabolism promotes tumor immune evasion by regulating the NOD/VISTA axis. Journal for ImmunoTherapy of Cancer, 11(12), e007487. https://doi.org/10.1136/jitc-2023-007487
Vancouver
Chen Y, Sun J, Liu J, Wei Y, Wang X, Fang H, et al. Aldehyde dehydrogenase 2-mediated aldehyde metabolism promotes tumor immune evasion by regulating the NOD/VISTA axis. Journal for ImmunoTherapy of Cancer. 2023;11(12):e007487. doi:10.1136/jitc-2023-007487
BibTeX
@article{Chen2023,
author = {Chen, Yuru and Sun, Jiazheng and Liu, Jiazhou and Wei, Yuxian and Wang, Xiaoyu and Fang, Huiying and Du, Huimin and Huang, Jing and Li, Qin and Ren, Guosheng and Wang, Xiaoyi and Li, Hongzhong},
title = {Aldehyde dehydrogenase 2-mediated aldehyde metabolism promotes tumor immune evasion by regulating the NOD/VISTA axis},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2023},
volume = {11},
number = {12},
pages = {e007487},
doi = {10.1136/jitc-2023-007487}
}
EUVIMED